New challenges for ACE-inhibitors in vascular diseases

Drug Design Reviews Online

Volumn 2, Issue 7, 2005, Pages 485-493

  Napoli, Claudio ^a,b   Loscalzo, Joseph ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

ACE; Atherosclerosis; Endothelium

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN; CAPTOPRIL; CILAZAPRIL; DELAPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; FOSINOPRIL; LOSARTAN; OLMESARTAN; PERINDOPRIL; QUINAPRIL; RAMIPRIL; SIMVASTATIN; VALSARTAN; ZOFENOPRIL;

ANGIOPLASTY; ANTICOAGULATION; ARTERY ENDOTHELIUM; ARTERY WALL; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL FUNCTION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG EFFECT; EXPERIMENTATION; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SIGNAL TRANSDUCTION; STROKE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS; VASCULAR ENDOTHELIUM; VASCULARIZATION;

EID: 27744549664     PISSN: 15672697     EISSN: 15672697     Source Type: Journal    
DOI: 10.2174/156726905774641190     Document Type: Review

References (98)

1. Ross, R., Atherosclerosis: an inflammatory disease. N. Engl. J. Med. 1999; 340: 115-26.
2. Ruberg, F.L., Leopold, J.A., Loscalzo, J. Atherothrombosis: plaque instability and thrombogenesis. Prog. Cardiovasc. Dis. 2002; 44: 381-94.
3. Napoli, C., D'Armiento, F.P., Mancini, F.P., Witztum, J.L., Palumbo, G., Palinski, W. Fatty streak formation occurs in human fetal aortas and is greatly enhanced by maternal hypercholesterolemia. Intimal accumulation of low density lipoprotein and its oxidation precede monocyte recruitment into early atherosclerotic lesions. J. Clin. Invest. 1997; 100: 2680-90.
4. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Natural history of aortic and coronary atherosclerotic lesions in youth. Findings from the PDAY Study. Arterioscler. Thromb. 1993; 13: 1291-8.
5. Berenson, G.S., Srinivasan, S.R., Bao, W., Newman, W.P., 3rd, Tracy, R.E., Wattigney, W.A. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. The Bogalusa Heart Study. N. Engl. J. Med. 1998; 338: 1650-6.
6. Napoli, C., Glass, C.K., Witztum, J.L., Deutsch, R., D'Armiento, F.P., Palinski, W. Influence of maternal hypercholesterolaemia during pregnancy on progression of early atherosclerotic lesions in childhood: Fate of Early Lesions in Children (FELIC) study. Lancet 1999; 354: 1234-41.
7. Napoli, C., Palinski, W. Maternal hypercholesterolemia during pregnancy influences the later development of atherosclerosis: clinical and pathogenic implications. Eur. Heart J. 2001; 22: 4-9.
8. Palinski, W., Napoli, C., The fetal origins of atherosclerosis: maternal hypercholesterolemia, and cholesterol-lowering or antioxidant treatment during pregnancy influence in utero programming and postnatal susceptibility to atherogenesis. FASEB J. 2002; 16: 1348-60.
9. D'Armiento, F.P., Bianchi, A., de Nigris, F., Capuzzi, D.M., D'Armiento, M.R., Crimi, G., Abete, P., Palinski, W., Condorelli, M., Napoli, C. Age-related effects on atherogenesis and scavenger enzymes of intracranial and extracranial arteries in men without classic risk factors for atherosclerosis. Stroke 2001; 32: 2472-80.
10. Lakatta, E.G., Levy, D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: Part I: aging arteries: a "set up" for vascular disease. Circulation 2003; 107: 139-46.
11. Loscalzo, J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ. Res. 2001; 88: 756-62.
12. Napoli, C., Ignarro, L.J. Nitric oxide and atherosclerosis. Nitric Oxide 2001; 5: 88-97.
13. Kranzhofer, R., Schmidt, J., Pfeiffer, C.A. et al., Angiotensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscler. Thromb. Vasc. Biol. 1999; 19: 1623-29.
14. Brasier, A.R., Jamaluddin, M., Han, Y. et al., Angiotensin II induces gene transcription through cell-type-dependent effects on the nuclear factor-kappaB (NF-kappaB) transcription factor. Mol. Cell Biochem. 2000; 212: 155-9.
15. Hernandez-Presa, M., Bustos, C., Ortego, M. et al., Angiotensinconverting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997; 95: 1532-41.
16. Usui, M., Egashira, K., Tomita, H. et al., Important role of local angiotensin II activity mediated via type 1 receptor in the pathogenesis of cardiovascular inflammatory changes induced by chronic blockade of nitric oxide synthesis in rats. Circulation 2000; 101: 305-10.
17. Diet, F., Pratt, R.E., Berry, G.J. et al. , Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation 1996; 94: 2756-67.
18. Keidar, S., Kaplan, M., Hoffman A., and Aviram, M., Angiotensin II stimulates macrophage-mediated oxidation of low density lipoproteins. Atherosclerosis 1995; 115: 201-15.
19. Leopold, J.A., Loscalzo, J. Clinical importance of understanding vascular biology. Cardiol. Rev. 2000; 8: 115-23.
20. Usui, M., Egashira, K., Kitamoto, S. et al., Pathogenic role of oxidative stress in vascular angiotensin-converting enzyme activation in long-term blockade of nitric oxide synthesis in rats. Hypertension 1999; 34: 546-51.
21. Schieffer, B., Schieffer, E., Hilfiker-Kleiner, D. et al. , Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability. Circulation 2000; 101: 1372-8.
22. Biasucci, L., Vitteli, A., Liuzzo, G. et al., Elevated levels of interleukin-6 in unstable angina. Circulation 1996; 94: 874-7.
23. Biswas, P., Delfanti, F., Mengozzi, M. et al., Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood 1998; 91: 258-65.
24. Kishimoto, T., Akira, S., Narazaki, M. and Taga, T. Interleukin-6 family of cytokines and gp 130. Blood 1995; 86: 1243-54.
25. Ikeda, U., Ikeda, M., Seino, Y. et al., Expression of intracellular adhesion molecule 1 in rat vascular smooth muscle cells by proinflammatory cytokines. Atherosclerosis 1993; 104: 61-8.
26. Gossmann, J., Burkhardt, R., Harder, S. et al., Effect of angiotensin II infusion with and without angiotensin II type 1 receptor blockade on nitric oxide metabolism and endothelin in human beings: a placebo-controlled study in healthy volunteers. Clin. Pharmacol. Ther. 2000; 68: 501-9.
27. Rajagopalan, S., Kurz, S., Munzel, T. et al., Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation: Contribution to alterations of vasomotor tone. J. Clin. Invest. 1996; 97: 1916-23.
28. Gryglewski, R.J., Palmer, R.M. and Moncada, S. Superoxide anion is involved in the breakdown of endothelium-derived vascular relaxing factor. Nature 1986; 320: 454-6.
29. Takemoto, M., Egashira, K., Usui, M. et al., Important role of tissue angiotensin-converting enzyme activity in the pathogenesis of coronary vascular and myocardial structural changes induced by long-term blockade of nitric oxide synthesis in rats. J. Clin. Invest. 1997; 99: 278-87.
30. Kitamoto, S., Egashira, K., Kataoka, C. et al., Chronic inhibition of nitric oxide synthesis in rats increases aortic superoxide anion production via the action of angiotensin II. J. Hypertens. 2000; 18: 1795-1800.
31. Katoh, M., Egashira, K., Usui, M. et al., Cardiac angiotensin II receptors are upregulated by long-term inhibition of nitric oxide synthesis in rats. Circ. Res. 1998; 83: 743-51.
32. Pueyo, M.E., Gonzalez, W., Nicoletti, A. et al., Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler. Thromb. Vasc. Biol. 2000; 20: 645-51.
33. Pastore, L., Tessitore, A., Martinotti, S. et al., Angiotensin II stimulates intercellular adhesion molecule-1 (ICAM-1) expression by human vascular endothelial cells, and increases soluble ICAM-1 release in vivo. Circulation 1999; 100: 1646-52.
34. Tummala, P.E., Chen, X.L., Sundell, C.L. et al., Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: A potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999; 100: 1223-9.
35. Chen, X.L., Tummala, P.E., Olbrych, M.T. et al., Angiotensin II induces monocyte chemoattractant protein-1 gene expression in rat vascular smooth muscle cells. Circ. Res. 1998; 83: 952-9.
36. Kuga, T., Mohri, M., Egashira, K. et al., Bradykinin-induced vasodilation of human coronary arteries in vivo: role of nitric oxide and angiotensin-converting enzyme. J. Am. Coll. Cardiol. 1997; 30: 108-112.
37. Nishimura, H., Tsuji, H., Masuda, H. et al., The effects of angiotensin metabolites on the regulation of coagulation and fibrinolysis in cultured rat aortic endothelial cells. Thromb. Haemost. 1999; 82: 1516-21.
38. Yusuf, S., Pepine, C.J., Garces C. et al., Effect of enalapril on myocardial infarction and unstable angina in patients with low ejection fractions. Lancet 1992; 340: 1173-78.
39. Pfeffer, M.A., Braunwald, E., Moye, L.A. et al., Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med. 1992; 327: 669-77.
40. Cleland, J.G., Erhardt, L., Murray, G. et al. , Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure: A report from the AIRE Study Investigators. Eur. Heart J. 1997; 18: 14-5.
41. Kober, L., Torp-Pedersen, C., Carlsen, J.E. et al., A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction: Trandolapril Cardiac Evaluation (TRACE) study group. N. Engl. J. Med. 1995; 333: 1670-6.
42. Flather, M.D., Yusuf, S., Kober, L. et al., Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet 2000; 355: 1575-81.
43. Domanski, M.J., Exner, D.V., Borkowf, C.B. et al., Effect of angiotensin converting enzyme inhibition on sudden cardiac death in patients following acute myocardial infarction: A meta-analysis of randomized clinical trials. J. Am. Coll. Cardiol. 1999; 33: 598-604.
44. Libby. P., Molecular bases of the acute coronary syndromes. Circulation 1995; 91: 2844-50.
45. Hernandez, A., Barberi, L., Ballerio, R. et al., Delapril slows the progression of atherosclerosis and maintains endothelial function in cholesterol-fed rabbits. Atherosclerosis 1998; 137: 71-6.
46. Varin, R., Mulder, P., Tamion, F. et al., Improvement of endothelial function by chronic angiotensin-converting enzyme inhibition in heart failure: role of nitric oxide, prostanoids, oxidant stress, and bradykinin. Circulation 2000; 100: 351-6.
47. Hornig, B., Arakawa, N., Haussmann, D. and Drexler, H. Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure. Circulation 1998; 98: 2842-8.
48. O'Driscoll, G., Green, D., Rankin, J. et al., Improvement in endothelial function by angiotensin converting enzyme inhibition in insulin-dependent diabetes mellitus. J. Clin. Invest. 1997; 100: 678-84.
49. Motz, W. and Strauer, B.E. Improvement of coronary flow reserve after long-term therapy with enalapril. Hypertension 1996; 27: 1031-8.
50. Higashi, Y., Sasaki, S., Nakagawa, K. et al., A comparison of angiotensin-converting enzyme inhibitors, calcium antagonists, beta-blockers and diuretic agents on reactive hyperemia in patients with essential hypertension: a multicenter study. J. Am. Coll. Cardiol. 2000; 35: 284-91.
51. Soejima, H., Ogawa, H., Yasue, H. et al. , Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction. J. Am. Coll. Cardiol. 1999; 34: 983-8.
52. Geisterfer, A.A., Peach, M.J. and Owens, G.K., Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ. Res. 1988; 62: 749-56.
53. Berk, B.C. and Corson, M.A., Angiotensin II signal transduction in vascular smooth muscle: role of tyrosine kinases. Circ. Res. 1997; 80: 607-17.
54. Kawano, H., Do, Y., Kawano, Y. et al., Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000; 101: 1130-7.
55. Otsuka, S., Sugano, M., Makino, N. et al., Interaction of mRNAs for angiotensin II type 1 and type 2 receptors to vascular remodeling in spontaneously hypertensive rats. Hypertension 1998; 32: 467-72.
56. Vaughan, D.E., Angiotensin and vascular fibrinolytic balance. Am J. Hypertens. 2002; 15: 3S-8S.
57. Zurbano, M.J., Anguera, I., Heras, M. et al., Captopril administration reduces thrombus formation and surface expression of platelet glycoprotein IIb/IIa in early postmyocardial infarction stage. Arterioscler. Thromb. Vasc. Biol. 1999; 19: 1791-5.
58. Feener, E.P., Northrup, J.M., Aiello, L.P., and King, G.L., Angiotensin II induces plasminogen activator inhibitor-1 and -2 expression in vascular endothelial and smooth muscle cells. J. Clin. Invest. 1995; 95: 1353-62.
59. Hamdan, A.D., Quist, W.C., Gagne, J.B. and Feener, E.P., Angiotensin-converting enzyme inhibition suppresses plasminogen activator inhibitor-1 expression in the neointima of balloon-injured rat aorta. Circulation 1996; 93: 1073-8.
60. Napoli, C., Cicala, C., D'Armiento, F.P., et al. Beneficial effects of ACE-inhibition with zofenopril on plaque formation and low-density lipoprotein oxidation in watanabe heritable hyperlipidemic rabbits. Gen. Pharmacol. 1999; 33: 467-77.
61. Mollace, V., Salvemini, D., Sessa, W.C., Vane, J.R. Inhibition of human platelet aggregation by endothelium-derived relaxing factor, sodium nitroprusside or iloprost is potentiated by captopril and reduced thiols. J. Pharmacol. Exp. Ther. 1991; 258: 820-3.
62. Lonn, E., Angiotensin-converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Atherosclerosis. Curr. Atheroscler. Rep. 2002; 4: 363-72.
63. Chobanian, A.V., Haudenschild, C.C., Nickerson, C., Drago, R., Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension 1990; 15: 327-31.
64. Aberg, G., Ferrer, P., Effects of captopril on atherosclerosis in cynomolgus monkeys. J. Cardiovasc. Pharmacol. 1990; 15 Suppl 5: S65-72.
65. Hayek, T., Attias, J., Smith, J., Breslow, J.L., Keidar, S., Antiatherosclerotic and antioxidative effects of captopril in apolipoprotein E-deficient mice. J. Cardiovasc. Pharmacol. 1998; 31: 540-4.
66. de Nigris, F., D'Armiento, F.P., Somma, P., et al. Chronic treatment with sulfhydryl angiotensin-converting enzyme inhibitors reduce susceptibility of plasma LDL to in vitro oxidation, formation of oxidation-specific epitopes in the arterial wall, and atherogenesis in apolipoprotein E knockout mice. Int. J. Cardiol. 2001; 81: 107-15.
67. Sun, Y.P., Zhu, B.Q., Browne, A.E., Pulukurthy, S., Chou, T.M., Sudhir, K., Glantz, S.A., Deedwania, P.C., Chatterjee, K., Parmley, W.W., Comparative effects of ACE inhibitors and an angiotensin receptor blocker on atherosclerosis and vascular function. J. Cardiovasc. Pharmacol. Ther. 2001; 6: 175-81.
68. Charpiot, P., Rolland, P.H., Friggi, A., Piquet, P., Scalbert, E., Bodard, H., Barlatier, A., Latrille, V., Tranier, P., Mercier, C., ACE inhibition with perindopril and atherogenesis-induced structural and functional changes in minipig arteries. Arterioscler. Thromb. 1993; 13: 1125-38.
69. Candido, R., Jandeleit-Dahm, K.A., Cao, Z., Nesteroff, S.P., Burns, W.C., Twigg, S.M., Dilley, R.J., Cooper, M.E., Allen, T.J., Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation 2002; 106: 246-53.
70. Kowala, M.C., Grove, R.I., Aberg, G., Inhibitors of angiotensin converting enzyme decrease early atherosclerosis in hyperlipidemic hamsters. Fosinopril reduces plasma cholesterol and captopril inhibits macrophage-foam cell accumulation independently of blood pressure and plasma lipids. Atherosclerosis 1994; 108: 61-72.
71. Hayek, T., Attias, J., Coleman, R., Brodsky, S., Smith, J., Breslow, J.L., Keidar, S., The angiotensin-converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering blood pressure in apolipoprotein E deficient mice. Cardiovasc. Res. 1999; 44: 579-87.
72. Li, J., Hirose, N., Kawamura, M., Arai, Y., Antiatherogenic effect of angiotensin converting enzyme inhibitor (benazepril) and angiotensin II receptor antagonist (valsartan) in the cholesterol-fed rabbits. Atherosclerosis 1999; 143: 315-26.
73. Keidar, S., Attias, J., Coleman, R., Wirth, K., Scholkens, B., Hayek, T., Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin. J. Cardiovasc. Pharmacol. 2000; 35: 64-72.
74. Hayek, T., Kaplan, M., Raz, A., Keidar, S., Coleman, R., Aviram, M., Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis. Atherosclerosis 2002; 161: 65-74.
75. Strawn, W.B., Chappell, M.C., Dean, R.H., Kivlighn, S., Ferrario, C.M., Inhibition of early atherogenesis by losartan in monkeys with diet-induced hypercholesterolemia. Circulation 2000; 101: 1586-93.
76. de las Heras, N., Aragoncillo, P., Maeso, R., Vazquez-Perez, S., Navarro-Cid, J., DeGasparo, M., Mann, J., Ruilope, L.M., Cachofeiro, V., Lahera, V., AT(1) receptor antagonism reduces endothelial dysfunction and intimal thickening in atherosclerotic rabbits. Hypertension 1999; 34(4 Pt 2): 969-75.
77. Miyazaki, M., Takai, S., Anti-atherosclerotic efficacy of olmesartan. J. Hum. Hypertens. 2002; 16 Suppl 2: S7-12.
78. MacMahon, S., Sharpe, N., Gamble, G. et al., Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease: PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J. Am. Coll. Cardiol. 2000; 36: 438-43.
79. Teo, K.K., Burton, J.R., Buller, C.E. et al., Long-term effects of cholesterol lowering, and angiotensin-converting enzyme inhibition on coronary atherosclerosis: the Simvastatin/Enalapril coronary atherosclerosis trial. Circulation 2000; 102: 1748-54.
80. Lonn, E.M., Yusuf, S., Dzavik, V. et al., Effects of ramipril and vitamin E on atherosclerosis: the Study to Evaluate Carotid Ultrasound Changes in Patients Treated with Ramipril and Vitamin E (SECURE). Circulation 2001; 103: 919-25.
81. The Heart Outcomes Prevention Evaluation Study Investigators, Effects of an angiotensin-converting-enzyme inhibitor ramipril, on cardiovascular events in high-risk patients. N. Engl. J. Med. 2000; 342: 145-53.
82. Farhy, R.D., Carretero, O.A., Ho K.L., and Scicli, A.G., Role of kinins and nitric oxide in the effects of angiotensin converting enzyme inhibitors on neointima formation. Circ. Res. 1993; 72: 1202-10.
83. Faxon, D.P. Effect of high dose angiotensin-converting enzyme inhibition on restenosis: final results of the MARCATOR Study, a multicenter, double-blind, placebo-controlled trial of cilazapril. The Multicenter American Research Trial with Cilazapril after Angioplasty to Prevent Transluminal Coronary Obstruction and Restenosis (MARCATOR) study group. J. Am. Coll. Cardiol. 1995; 25: 362-9.
84. MERCATOR Study Group, Does the new angiotensin converting enzyme inhibitor cilazapril prevent restenosis after percutaneous transluminal coronary angioplasty? Results of the MERCATOR study: a multicenter, randomized, double-blind placebo-controlled trial. Circulation 1992; 86: 100-110.
85. Cashin-Hemphill, L., Holmvang, G., Chan, R.C. et al., Angiotensin-converting enzyme inhibition as antiatherosclerotic therapy: no answer yet. QUIET Investigators. QUinapril Ischemic Event Trial. Am. J. Cardiol. 1999; 83: 43-7.
86. The Heart Outcomes Prevention Evaluation Study Investigators, Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 2000; 355: 253-9.
87. Fox, K.M., Henderson, J.R., Bertrand, M.E.et al., The European trial on reduction of cardiac events with perindopril in stable coronary artery disease (EUROPA). Eur. Heart J. 1998; 19 suppl: J52-J55.
88. Pfeffer, M., Domanski, M., Rosenberg, Y. et al., Prevention of events with angiotensin-converting enzyme inhibition (the PEACE study design). Am. J. Cardiol. 1998; 82 suppl: 25H-30H.
89. Bots, M.L., Remme, W.J., Luscher, T.F., Grobbee, D.E., PERindopril-Function of the Endothelium in Coronary Artery Disease Trial: The PERFECT Study-Sub Study of EUROPA: Rationale and Design. Cardiovasc. Drugs Ther. 2002; 16: 227-36
90. Anderson, T.J., Elstein, E., Haber H., and Charbonneau, F., Comparative study of ACE-inhibition, angiotensin II antagonism, and calcium channel blockade on flow-mediated vasodilation in patients with coronary disease. J. Am. Coll. Cardiol. 2000; 35: 60-6.
91. Prasad, A., Narayanan, S., Husain, S. et al., Insertion-deletion polymorphism of the ACE gene modulates reversibility of endothelial dysfunction with ACE inhibition. Circulation 2000; 102: 35-41.
92. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group, ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. Lancet 1995; 345: 669-85.
93. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico, GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Lancet 1994; 343: 1115-22.
94. Libby, P., Aikawa, M., Stabilization of atherosclerotic plaques: New mechanisms and clinical targets. Nat. Med. 2002; 8: 1257-62.
95. Palinski W, Napoli C. Unraveling pleiotropic effects of statins on plaque rupture. Arterioscler. Thromb. Vasc. Biol. 2002; 22: 1745-50.
96. Napoli, C., Witztum, J.L., de Nigris, F., Palumbo, G., D'Armiento, F.P., Palinski, W., Intracranial arteries of human fetuses are more resistant to hypercholesterolemia-induced fatty streak formation than extracranial arteries. Circulation 1999; 99: 2003-10.
97. O'Keefe, J.H., Lurk, J.T., Kahatapitiya, R.C., Haskin, J.A., The Renin-Angiotensin-aldosterone system as a target in coronary disease. Curr. Atheroscler. Rep. 2003; 5: 124-30.
98. Natesh, R., Schwager, S. L. U., Sturrock, E. D., Acharya, K. R., Crystal structure of the human angiotensin-converting enzymelisinopril complex. Nature 2003; 421: 551-4.